[Form 4] ATAI Life Sciences N.V. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing overview: On 06/27/2025 ATAI Life Sciences N.V. (symbol: ATAI) reported a change in beneficial ownership by Christian Angermayer, who is both a Director and 10% owner.

Key transaction: On 06/26/2025 the insider received a stock option covering 103,000 common shares at an exercise price of $2.25 per share. The award was coded "A" (grant or award) and is held directly by the reporting person.

Vesting & expiration: The option vests on the earlier of (i) the day before ATAIs next annual shareholder meeting or (ii) 06/26/2026, and it expires on 06/26/2035. No deemed execution date or other conditions were noted.

Post-transaction holdings: Following the grant, Mr. Angermayer beneficially owns 103,000 derivative securities (stock options). Table I shows no non-derivative share acquisitions or dispositions.

Investor take-away: The filing reflects a routine equity incentive grant rather than an open-market purchase or sale, so it carries limited immediate signalling value. The award incrementally increases potential dilution but has no direct impact on ATAIs cash position or current share count.

Insights

Securities Analyst

TL;DR: Routine option grant to insider; minimal near-term impact on valuation or sentiment.

The Form 4 discloses a single award of 103,000 options at $2.25 to Christian Angermayer. Because the grant is compensation-related, it neither injects cash nor reflects insider buying pressure. The 10-year term and one-year vesting are standard for director options. With no accompanying stock sale or purchase, market interpretation should be neutral; dilution is marginal given ATAI’s multi-million-share base. I therefore view the filing as informational rather than price-moving.

Corporate Governance Expert

TL;DR: Standard board incentive aligns director with shareholders; governance profile unchanged.

Granting options to a major shareholder-director aligns oversight incentives but is commonplace for U.S.-listed corporates. The vesting schedule—earlier of next AGM or one year—ties compensation to ongoing service without imposing onerous performance triggers. No 10b5-1 checkbox was marked, indicating this is not a pre-planned trading program but a straightforward award. From a governance lens there is no red flag, nor does the award materially shift control, as the holder already exceeds 10% ownership. Impact on governance score: neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Angermayer Christian

(Last) (First) (Middle)

66 & 67, BEATRICE, AMERY STREET

(Street)

SLIEMA O1 SLM1707

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ATAI Life Sciences N.V. [ ATAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.25	06/26/2025		A		103,000		(1)	06/26/2035	Common Shares	103,000	$0	103,000	D

Explanation of Responses:

1. The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026.

	/s/ Ryan Barrett, Attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did ATAI report in the latest Form 4?

ATAI disclosed that Director and 10% owner Christian Angermayer received a grant of 103,000 stock options on 06/26/2025.

How many ATAI stock options were granted and at what exercise price?

103,000 options with an exercise price of $2.25 per share.

When do Christian Angermayers newly granted ATAI options vest and expire?

They vest on the earlier of the day before the next annual meeting or 06/26/2026 and expire on 06/26/2035.

Did the Form 4 show any open-market purchases or sales of ATAI common stock?

No. Table I lists no non-derivative share transactions; only a derivative option award was reported.

What is Christian Angermayers ownership position after the reported transaction?

He beneficially owns 103,000 derivative securities (stock options) directly.